medigraphic.com
ISSN 0001-0944 (Print)
Órgano Oficial de la Asociación Dental Mexicana

2021, Number 5

<< Back Next >>

Rev ADM 2021; 78 (5)

Johnson & Johnson vaccine against COVID-19: worldwide vaccine distribution, mechanism of action, indications, contraindications and side effects. A literature review.

Pineda-Palacios WG, Rivas-Astudillo JA, Saraguro-León GA, Solano-Espinoza JA, Valdivieso-Tocto NK, Álvarez-Álvarez DP

Language: Spanish
References: 20
Page: 275-279
PDF size: 176.56 Kb.


ABSTRACT

The SARS-CoV-2, which caused us to be experiencing a global pandemic, had its origins in China, from where it has crossed borders rapidly, reaching all corners of the world. Many research teams have faced the challenge of getting a vaccine to fight this deadly virus. For this reason, this research aimed to analyze the literature on the Johnson & Johnson COVID-19 vaccine: global distribution of the vaccine, mechanism of action, indications, contraindications and side effects. Several studies show that its effectiveness varies according to the age and gender of each individual, but this vaccine reached a moderate degree of certainty. The adverse effects are mostly mild and resolved within two days, with some exceptions being a rare adverse effect called prevalent thrombocytopenia in women aged 18 to 40 years. For this reason, the FDA recommends caution in the use of the vaccine with respect to this potentially fatal adverse effect in some cases.


REFERENCES

  1. Zhao J, Zhao S, Ou J, Zhang J, Lan W, Guan W et al. COVID-19: Coronavirus vaccine development updates. Front Immunol. 2020; 11: 602256. doi: 10.3389/fimmu.2020.602256.

  2. Kounis NG, Koniari I, de Gregorio C, Velissaris D, Petalas K, Brinia A et al. Allergic reactions to current available COVID-19 vaccinations: pathophysiology, causality, and therapeutic considerations. Vaccines (Basel). 2021; 9 (3): 221.

  3. Picazo J. Vacuna frente al COVID-19. Sociedad Española de Quimioterapia: infección y vacunas. 2019. Disponible en: https://seq.es/wp-content/uploads/2020/12/vacunas-covid-2.5.pdf

  4. Soldevilla PJ, Cardona PJ, Cayla JA, Hernández A, Palma D, Rius C. Revisión sobre las vacunas frente a SARS-CoV-2. Enf Emerg. 2021; 20 (1): 7-1. Disponible en: https://www.uitb.cat/wp-content/uploads/2021/02/Review-vacunas-COVID_Final_16022021.pdf

  5. Gaus D. COVID-19: vacunas. Práctica Familiar Rural. 2021; 6 (1). Disponible en: https://www.practicafamiliarrural.org/index.php/pfr/article/view/196/226

  6. De Francisco ALM. Vacunas SARS-COV2 marzo 2021. Nefrología al día. 2020. Disponible en: https://static.elsevier.es/nefro/monografias/1/366/366_110320211742.pdf

  7. Holm MR, Poland GA. Critical aspects of packaging, storage, preparation, and administration of mRNA and adenovirus-vectored COVID-19 vaccines for optimal efficacy. Vaccine. 2021; 39 (3): 457-459. doi: 10.1016/j.vaccine.2020.12.017.

  8. Sadoff J, Gray G, Vandebosch A, Cárdenas V, Shukarev G, Grinsztejn B et al. Safety and efficacy of single-dose Ad26.COV2.s vaccine against Covid-19. N Engl J Med. 2021; 384 (23): 2187-2201. doi: 10.1056/NEJMoa2101544.

  9. Ledford H. COVID vaccines and blood clots: five key questions. Nature. 2021; 592 (7855): 495-496. doi: 10.1038/d41586-021-00998-w.

  10. MacNeil JR, Su JR, Broder KR et al. Recomendaciones actualizadas del Comité Asesor sobre Prácticas de Inmunización para el uso de la vacuna COVID-19 de Janssen (Johnson & Johnson) después de informes de trombosis con síndrome de trombocitopenia entre receptores de la vacuna - Estados Unidos, abril de 2021. MMWR Morb Mortal Wkly Rep. 2021; 70: 651-656. Disponible en: http://dx.doi.org/10.15585/mmwr.mm7017e4

  11. Janssen Biotech, Inc. (2021, 26 febrero). FDA Briefing Document Janssen Ad26.COV2.S Vaccine for the Prevention of COVID-19. Vaccines and Related Biological Products Advisory Committee Meeting February 26, 2021. Available in: https://www.fda.gov/media/146217/download

  12. Oliver SE, Gargano JW, Scobie H, Wallace M, Hadler SC, Leung J et al. The advisory committee on immunization practices' interim recommendation for use of Janssen COVID-19 vaccine - United States, February 2021. MMWR Morb Mortal Wkly Rep. 2021; 70 (9): 329-332. doi: 10.15585/mmwr.mm7009e4.

  13. Organización Mundial de la Salud. Vacuna de Janssen contra la COVID-19. Ginebra, Suiza: OMS; 2021.

  14. Roozendaal R, Solforosi L, Stieh D, Serroyen J, Straetemans R, Wegmann F et al. SARS-CoV-2 binding and neutralizing antibody levels after vaccination with Ad26.COV2.S predict durable protection in rhesus macaques. bioRxiv J. 2021. Avaialbe in: https://doi.org/10.1101/2021.01.30.428921

  15. Drugs and Lactation Database (LactMed). Bethesda (MD): National Library of Medicine (US); 2021. COVID-19 vaccines. Available in: https://www.ncbi.nlm.nih.gov/books/NBK565969/

  16. D'Amico F, Rabaud C, Peyrin-Biroulet L, Danese S. SARS-CoV-2 vaccination in IBD: more pros than cons. Nat Rev Gastroenterol Hepatol. 2021; 18 (4): 211-213. doi: 10.1038/s41575-021-00420-w.

  17. Livingston EH, Malani PN, Creech CB. The Johnson & Johnson vaccine for COVID-19. JAMA. 2021; 325 (15): 1575. doi: 10.1001/jama.2021.2927.

  18. Stephenson KE, Le Gars M, Sadoff J, de Groot AM, Heerwegh D, Truyers C et al. Immunogenicity of the Ad26.COV2.S vaccine for COVID-19. JAMA. 2021; 325 (15): 1535-1544.

  19. Jhaveri R. The next set of COVID-19 vaccines: leveraging new development platforms to increase access for more people around the world. Clin Ther. 2021; 43 (4): 702-710.

  20. MUH (FV). Vacuna frente a la COVID-19 de Janssen: conclusiones de la evaluación del riesgo de trombosis junto con trombocitopenia: Conclusiones del comité para la evaluación de riesgos en farmacovigilancia Europeo. Agencia española de medicamentos y productos sanitarios. 07/2021. Disponible en: https://www.aemps.gob.es/informa/notasInformativas/medicamentosUsoHumano/seguridad/2021/docs/NI_MUH_FV-07-2021-Janssen.pdf?x58195




2020     |     www.medigraphic.com